Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Triple therapy aims to cure High-Risk skin cancer without disfigurement

NCT ID NCT07251413

First seen Jan 05, 2026 · Last updated Jun 16, 2026 · Updated 30 times

Summary

This study tests whether combining an immunotherapy drug (cemiplimab), a topical cream (imiquimod), and laser therapy before surgery can cure high-risk basal cell skin cancer. About 18 adults with large or difficult-to-treat tumors will receive the combination or immunotherapy alone. The goal is to increase the chance of a definitive cure and reduce the need for disfiguring surgery.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BASAL CELL CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hospital Clínic de Barcelona. Carrer de Villarroel, 170, L'Eixample

    RECRUITING

    Barcelona, Barcelona, 08036, Spain

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hospital Miguel Servet de Zaragoza. P.º de Isabel la Católica, 1-3

    RECRUITING

    Zaragoza, Zaragoza, 5009, Spain

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hospital Ramón y Cajal. M-607, Km. 9, 100, Fuencarral-El Pardo,

    RECRUITING

    Madrid, Madrid, 28034, Spain

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hospital Universitario Dexeus - Grupo Quirónsalud. Carrer de Sabino Arana, 19 Ed, Distrito de Les Corts

    RECRUITING

    Barcelona, Barcelona, 08028, Spain

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

basal cell carcinoma skin basal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.